Literature DB >> 1550697

Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).

C De Mey1, I Meineke.   

Abstract

Plasma and urine concentrations of 5-ASA and its N-acetyl metabolite 5-AcASA were measured over 48 h in 12 young healthy male subjects, who received three doses of three times enteric coated 500 mg 5-ASA tablets at 7 h interval, on two occasions 14 days apart. On one occasion the doses were given after standard meals; on the other occasion, they were given 1 h before meals. Administration of the tablets after meals delayed systemic drug absorption but did not affect the extent of absorption. There was a sharp rise in the plasma concentrations of 5-ASA and 5-AcASA in the early morning (i.e. circa 24 h after administration of the 1st dose) independent of when the tablets were taken with respect to the meals. This suggests that tablets or tablet fragments remained in the stomach until the later part of the night. Thus, diurnal effects may be more important than prandial effects in the evaluation of the kinetics of 5-ASA and its metabolites after peroral administration of enteric coated tablets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550697      PMCID: PMC1381304          DOI: 10.1111/j.1365-2125.1992.tb04021.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  A distribution-free procedure for the statistical analysis of bioequivalence studies.

Authors:  D Hauschke; V W Steinijans; E Diletti
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-02

2.  Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet.

Authors:  J G Hardy; J N Healey; S W Lee; J R Reynolds
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

3.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

4.  Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography.

Authors:  E Brendel; I Meineke; D Witsch; M Zschunke
Journal:  J Chromatogr       Date:  1987-01-09

5.  Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.

Authors:  S A Riley; I A Tavares; A Bennett; V Mani
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

  5 in total
  7 in total

Review 1.  Chronopharmacokinetics. Current status.

Authors:  B Bruguerolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 2.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 3.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

Authors:  F N Hussain; R A Ajjan; S A Riley
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 5.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].

Authors:  J Keller; H Goebell; U Klotz; P Layer
Journal:  Med Klin (Munich)       Date:  1998-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.